Method for making multispecific antibodies having heteromultimeric and common components

• US 8,765,412 B2
• Filed: 09/29/2006
• Issued: 07/01/2014
• Est. Priority Date: 05/02/1997
• Status: Expired due to Fees

• Current Assignee: Genentech, Inc. (Roche Holding AG)
• Original Assignee: Genentech, Inc. (Roche Holding AG)
• Inventors: Arathoon, W. Robert, Carter, Paul J., Merchant, Anne M., Presta, Leonard G.
• Primary Examiner(s): Shukla, Ram R
• Assistant Examiner(s): HOLLERAN, ANNE L
• Application Number:
  US11/536,951
• Publication Number:
  US 20070098712A1
• Time in Patent Office: 2,832 Days
• Field of Search: 530/387.3, 530/387.1, 536/23.53, 435/328, 435/69.6, 435/69.1, 435/69.7, 435/70.1, 435/71.1, 435/455, 435/326, 435/972
• US Class Current: 435/69.6
• CPC Class Codes: C07K 16/00 Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies antibodies with enzymatic activity, e.g. abzymes C12N9/0002
• CPC Class Codes: C07K 16/46 Hybrid immunoglobulins hybrids of an immunoglobulin with a peptide not being an immunoglobulin C07K19/00
• CPC Class Codes: C07K 16/468 Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
• CPC Class Codes: C07K 2317/732 Antibody-dependent cellular cytotoxicity [ADCC]

Abstract

The invention relates to a method of preparing heteromultimeric polypeptides such as bispecific antibodies, bispecific immunoadhesins and antibody-immunoadhesin chimeras. The invention also relates to the heteromultimers prepared using the method. Generally, the method provides a multispecific antibody having a common light chain associated with each heteromeric polypeptide having an antibody binding domain. Additionally the method further involves introducing into the multispecific antibody a specific and complementary interaction at the interface of a first polypeptide and the interface of a second polypeptide, so as to promote heteromultimer formation and hinder homomultimer formation; and/or a free thiol-containing residue at the interface of a first polypeptide and a corresponding free thiol-containing residue in the interface of a second polypeptide, such that a non-naturally occurring disulfide bond is formed between the first and second polypeptide. The method allows for the enhanced formation of the desired heteromultimer relative to undesired heteromultimers and homomultimers.

Claims

1. A method of preparing a heteromultimeric multispecific antibody comprising the steps of:

(i) culturing a host cell comprising recombinant nucleic acids which encode a first heavy chain polypeptide, a second heavy chain polypeptide, and a common light chain polypeptide, such that the polypeptides are expressed and form a heteromultimeric multispecific antibody,

wherein the first heavy chain polypeptide and the second heavy chain polypeptide each comprise a heavy chain constant domain and a heavy chain variable domain, wherein said first heavy chain polypeptide and said common light chain polypeptide form a binding domain that binds a first antigen, and wherein said second heavy chain polypeptide and said common light chain polypeptide form a binding domain that binds a different antigen, wherein the common light chain is the only light chain expressed in the host cell, and wherein said first heavy chain polypeptide and said second heavy chain polypeptide multimerize to form a heteromultimeric multispecific antibody; and

(ii) recovering the multispecific antibody from the host cell culture.

2. The method of claim 1 wherein the first and second heavy chain polypeptides each further comprise a multimerization domain, and wherein the first and second heavy chain polypeptides multimerize by interaction of the first and second multimerization domains to form a heteromultimeric multispecific antibody.

3. The method of claim 2 further comprising a non-naturally occurring disulfide bond between the first and second heavy chain polypeptides.

4. The method of claim 3, wherein the multimerization domain of either the first heavy chain polypeptide or the second heavy chain polypeptide, or of both the first heavy chain polypeptide and the second heavy chain polypeptide, is altered by amino-acid substitution to form the non-naturally occurring disulfide bond between a free thiol-containing residue in the multimerization domain of the first heavy chain polypeptide and a free thiol-containing residue in the multimerization domain of the second heavy chain polypeptide.

5. The method of claim 3, wherein the multimerization domain is at least a part of a C_H3 domain region of an antibody constant domain, and the non-naturally occurring disulfide bond is between the C_H3 multimerization domains of the first and second heavy chain polypeptides.

6. The method of claim 2 wherein the multimerization domains of the first and second heavy chain polypeptides interact at an amino acid side chain protuberance of one of the polypeptides and an amino acid side chain cavity of the other polypeptide.

7. The method of claim 2 wherein the formation of the heteromultimeric multispecific antibody comprises a protuberance-into-cavity interaction between the multimerization domains, and wherein the method further comprises before step (i):

providing a first nucleic acid encoding the first heavy chain polypeptide wherein the first nucleic acid is altered to encode an amino acid residue having a larger side chain volume, thereby generating a protuberance on the first heavy chain polypeptide multimerization domain, and

providing a second nucleic acid encoding the second heavy chain polypeptide wherein the second nucleic acid is altered to encode an amino acid residue having a smaller side chain volume, thereby generating a cavity on the second heavy chain polypeptide multimerization domain wherein the protuberance is positioned to interact with the cavity.

8. The method of claim 7, wherein the step of generating a protuberance or generating a cavity, or both, occurs by phage display selection.

9. The method of claim 7, wherein the amino acid residue having a larger side chain volume than the substituted amino acid is selected from the group consisting of arginine (R), phenylalanine (F), tyrosine (Y), tryptophan (W), isoleucine (I) and leucine (L).

10. The method of claim 7 wherein the amino acid residue having a smaller side chain volume than the substituted amino acid is selected from the group consisting of glycine (G), alanine (A), serine (S), threonine (T), and valine (V), and wherein the import residue is not cysteine (C).

11. The method of claim 1, wherein the heavy chain constant domain is the heavy chain constant domain of an IgG.

12. The method of claim 11 wherein the IgG is a human IgG.

13. The method of claim 1, wherein the heavy chain constant domain is a C_H3 domain.

14. The method of claim 13 wherein the C_H3 domain is a human C_H3 domain.

15. An isolated host cell comprising recombinant nucleic acid encoding a heteromultimeric multispecific antibody comprising a first heavy chain polypeptide, a second heavy chain polypeptide, and a common light chain polypeptide, wherein each heavy chain polypeptide comprises a heavy chain constant domain and a heavy chain variable domain, wherein said first heavy chain polypeptide and said common light chain polypeptide form a binding domain that binds a first antigen, and wherein said second heavy chain polypeptide and said common light chain polypeptide form a binding domain that binds a different antigen, wherein the common light chain is the only light chain expressed in the host cell, and wherein said first heavy chain polypeptide and said second heavy chain polypeptide multimerize to form a heteromultimeric multispecific antibody.

16. The host cell of claim 15 wherein the isolated host cell is a mammalian cell.